drug
tobramycin
Marketedupdated 3mo agoby Hikma Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6indications
investigational
Cystic Fibrosis
all catalysts(0)
nothing on the calendar yet
Trials studying tobramycin
- phase2Abbreviated Protocol for Two-Stage Exchange
- phase2A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
- N/ACystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
- N/AMulticenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities
- phase3Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 12, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Nov 4, 2030formulationUS 102070664.2y
- Sep 12, 2028formulationUS 88697942.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that